New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof

a technology of osteoclast differentiation and new compounds, which is applied in the direction of drug compositions, heterocyclic compound active ingredients, organic chemistry, etc., can solve the problems of cancer patients' death, cancer, and uncertain cause of cancer, and achieve inhibitory effect on osteoclast differentiation and inhibitory effect on nf-b transcription

Inactive Publication Date: 2014-01-30
METACINE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]The pharmaceutical composition according to the present invention has inhibitory effect on osteoclast differentiation and the inhibitory effect on NF-κB transcription. Thus, they can be used for preventing or treating metabolic bone disease selected from the groups consisting of bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone and Paget's disease.

Problems solved by technology

While the studies researched that the breast cancer can be caused by environmental and genetic factors, a certain cause of the cancer has not yet been identified.
It means that an increased incidence of breast cancer depends on a longer exposure period to estrogen.
The metastasis of cancer often leads to death in cancer patients, especially the breast cancer is recurred by a bone metastasis.
First, a high blood stream mobility following to a lot of blood flow around the red bone marrow of breast cancer cells causes to high access of breast cancer cells to bone tissues.
Pharmacokinetically, pyrophosphates having P—O—P can be easily hydrolyzed however, bisphosphonates having P—C—P cannot be easily hydrolyzed and thus it has relatively long-term half-life.
Also, the bisphosphonates increases the possibility of occurrence of BIONJ by blocking a sufficient blood supply through the inhibition of blood vessels by bisphosphonates.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof
  • New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof
  • New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

The Preparation of Compound 4

[0201]

TABLE 1Substituents of Compound 4NoRNoRa2,6-diisopropylphenylbphenylc2-chlorophenyld3-chlorophenyle4-chorophenylf2-trifluoropentylphenylgcyclohexylh4-carboxy-3-hydroxyphenyli3-caboxy-4-hydroxyphenylj2-fluorophenylK3-fluorophenyll4-fluorophenylmbenzyln2-fluorobenzylo3-fluorobenzylp4-fluorobenzylqphenethylr2-fluorophenethyls3-fluorophenethylt4-fluorophenethyl

(1) 3,4-diphenylfuran-2,5-dione (3)

[0202]After dissolving compound 2 (19.6 g, 96.0 mmol) in acetic anhydride (250 ml), Compound 1 (18.0 g, 80.0 mmol) is added thereto. After 6 hours of reaction with reflux, the temperature was reduced to room temperature, three times extractions were carried out with EA and seven times washings were carried out with brine. Water was removed with anhydrous sodium sulfate and to remove the remaining phenyl acetic acid, the column chromatography was carried out with EA / HX (1 / 2). After the distillation under the reduced pressure for the removal of the solvents conduc...

example 2

The preparation of Compounds 5, 6 and 7

[0225]

(1) The synthesis of N,2-diphenylacetamide (5a)

[0226]After dissolving compound 2 (1.00 g, 7.34 mmol) in MC (30 ml), the activation for 30 minutes was carried out by the addition of DCC (1.82 g, 8.81 mmol). After the sufficient activation, aniline (0.75 g, 8.07 mmol) was added thereto and the agitation for 6 hours was carried out at room temperature. After the identification of the reaction progress with TLC, DCU was removed by the filtration and solvents were removed by the distillation under the reduced pressure. Then, the next reaction was followed without the purification process.

(2) The synthesis of N-(2-chlorophenyl)-2-phenylacetamide (5b)

[0227]After dissolving compound 2 (5.00 g, 36.7 mmol) in MC (50 ml), the activation for 30 minutes was carried out by the addition of DCC (9.10 g, 44.5 mmol). After the sufficient activation, 2-chloroaniline (5.15 g, 40.4 mmol) was added thereto and the agitation for 6 hours was carried out at room ...

example 3

The Preparation of Compound 8

[0242]

[0243]The synthesis of 5-hydroxy-1,3,4-triphenyl-1H-pyrrol-2(5H)-one(8)

[0244]After the addition of compound 4e (1.00 g, 2.78 mmol) in methanol, NaBH4 was slowly added thereto in acetone-ice bath and the agitation for 3 hours was carried out at room temperature. After the identification of disappearance of compound 4e with TLC, quenching was carried out with in HCL aqueous solution in the ice bath. Then, three times extractions were carried out with EA and three times washings were carried out with brine. Water was removed by using Na2SO4, solvents were removed and then, the column chromatography was carried out with EA / HX (1 / 4). After the distillation under the reduced pressure, vacuum drying was carried out to obtain compound 8

[0245]white solid (0.71 g, 70.9%); mp 186-187° C.; IR (KBr, cm−1) 3326, 1672; 1H NMR (CDCl3-d) δ 6.325-6.503 (m, 1H), 7.279-7.476 (m, 12H), 7.847-7.869 (m, 2H); 13C NMR (CDCl3-d) δ 82.205, 121.498, 127.793, 127.884, 128.043,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

New compounds and pharmaceutical compositions comprising active ingredients having inhibition effects on osteoclast differentiation are provided. The pharmaceutical compositions comprising the new compounds can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone, and Paget's disease.

Description

CROSS-REFERENCES TO RELATED APPLICATION[0001]This patent application claims the benefit of priority from Korean Patent Application No. 10-2012-0082248 filed on Jul. 27, 2012, the contents of which are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to new compounds and pharmaceutical compositions comprising them, which have inhibition effects on osteoclast differentiation. The pharmaceutical composition comprising new compounds according to the present invention can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone and Paget's disease.[0004]2. Description of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D207/452C07D207/20C07D207/38
CPCA61K31/4015A61P19/00A61P35/00C07D207/20C07D207/38C07D207/408C07D207/444C07D207/448C07D207/452C07D207/456C07D409/04A61K31/40
Inventor PARK, BAE KEUNYOON, SUNG-HWAPARK, JU-YOUNGPARK, SUNG HOON
Owner METACINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap